Ovarian cancer · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
IP Carboplatin and Paclitaxel Variant #01 | — | R 3 174 | 21d | ~23.5 mo | — | ~6 | ~R 19 042 PFS proxy · indirect | 1 |
IP Cisplatin and Paclitaxel Variant #02 | — | R 1 609 | 21d | — | ~65.6 mo | ~6 | ~R 9 654 PFS proxy · indirect | — |
Cisplatin and Paclitaxel (TP) Variant #02 | — | R 1 315 | 21d | ~16.4 mo | ~35.6 mo | ~7 | ~R 9 204 PFS proxy · indirect | 3 |
Cisplatin and Cyclophosphamide Variant #01 | — | R 839 | 21d | — | — | ~6 | ~R 5 034 indirect | — |
IP Cisplatin and Cyclophosphamide Variant #01 | — | R 739 | 21d | — | — | ~6 | ~R 4 432 indirect | — |
5 of 5 regimens shown